



August 6, 2015

Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe, life-threatening diseases, today announced that management will be presenting at two upcoming investor conferences in August:

- **2015 Wedbush PacGrow Healthcare Conference.** Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present a company overview at 9:10 a.m. ET on Tuesday, August 11, 2015 in New York City.
- **Canaccord Genuity 35th Annual Growth Conference.** Scott Wolchko, Chief Operating and Financial Officer, will present a company overview at 2:30 p.m. ET on Wednesday, August 12, 2015 in Boston.

A live webcast of the presentations will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website for 30 days after the conference.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe, life-threatening diseases. The Company's lead product candidate, PROHEMA®, is a programmed hematopoietic cell-based immunotherapeutic, which is currently in clinical development in patients undergoing hematopoietic cell transplantation. The Company is also developing a PD-L1 programmed CD34+ cell immunotherapeutic for the treatment of autoimmune diseases and is leveraging its proprietary induced pluripotent stem cell platform to develop natural killer cell and T-cell cancer immunotherapeutics. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

CONTACT: Jesse Baumgartner, Stern Investor Relations, Inc.

212.362.1200, jesse@sternir.com